Top of the morning to you, and a fine one it is. Clear blue skies are hovering over the Pharmalot campus, where a cool breeze is wafting by and the official mascots are bounding about the grounds in search of critters. As for us, we are engaged in the usual rituals of brewing cups of stimulation — our choice today is orange creme — and foraging for items of interest. On that note, please enjoy the latest menu of tidbits we have assembled for you. As always, we hope your journey is meaningful and productive, and that you conquer the world. And of course, do keep in touch. Secret dossiers and saucy secrets are especially welcomed. …
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk’s Wegovy, Reuters says. With some analysts predicting a weight loss market reaching $100 billion a year or more by the end of the decade, executives at some of the world’s largest drugmakers — Sun Pharma, Cipla, Dr Reddy’s, and Lupin — all say they have started work on versions of Wegovy. And analysts say the move by these companies could go a long way toward improving global access to weight loss drugs and make them far more affordable.
Across the U.S., parents are spending weeks and even months searching — at times without success — for Beyfortus, a new monoclonal antibody that promises to reduce drastically infants’ chances of serious illness from RSV, The Wall Street Journal writes. A bumpy rollout of the shot is tarnishing what otherwise promised to be a radically different RSV season, with the hunt for doses especially difficult for parents with commercial insurance. Meanwhile, the U.S. government has hundreds of thousands of doses that remain unused through a federal program reserved for at-risk children.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect